ReviewDrug delivery and translational research2017
Nanoengineered strategies for siRNA delivery: from target assessment to cancer therapeutic efficacy.
Review in Drug delivery and translational research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 33 citations in OpenAlex.
- siRNA-based strategies to combat drug resistance in gastric cancer.Medical oncology (Northwood, London, England) · 2024Review
- Functionalized siRNA-chitosan nanoformulations promote triple-negative breast cancer cell death via blocking the miRNA-21/AKT/ERK signaling axis: in-silico and in vitro studies.Naunyn-Schmiedeberg's archives of pharmacology · 2024Article
- siRNA-based nanotherapeutics as emerging modalities for immune-mediated diseases: A preliminary review.Cell biology international · 2022Review
- Emerging trends in the nanomedicine applications of functionalized magnetic nanoparticles as novel therapies for acute and chronic diseases.Journal of nanobiotechnology · 2022Review
- Trimethyl-Chitosan Coated Gold Nanoparticles Enhance Delivery, Cellular Uptake and Gene Silencing Effect of EGFR-siRNA in Breast Cancer Cells.Frontiers in molecular biosciences · 2022Article
- Cationic Peptide-Modified Gold Nanostars as Efficient Delivery Platform for RNA Interference Antitumor Therapy.Polymers · 2021Article
- Synthesis and Properties of Targeted Radioisotope Carriers Based on Poly(Acrylic Acid) Nanogels.Pharmaceutics · 2021Article
- Nanotechnology in reproductive medicine: Opportunities for clinical translation.Clinical and experimental reproductive medicine · 2020Article
- Bioengineered siRNA-Based Nanoplatforms Targeting Molecular Signaling Pathways for the Treatment of Triple Negative Breast Cancer: Preclinical and Clinical Advancements.Pharmaceutics · 2020Review
- Downregulation of long non-coding RNA LINP1 inhibits the malignant progression of esophageal squamous cell carcinoma.Annals of translational medicine · 2020Article
- Steering the Clinical Translation of Delivery Systems for Drugs and Health Products.Pharmaceutics · 2020Article
- Aptamers as Delivery Agents of siRNA and Chimeric Formulations for the Treatment of Cancer.Pharmaceutics · 2019Review
- Clinical values of Ku80 upregulation in superficial esophageal squamous cell carcinoma.Cancer medicine · 2018Article
- Current Trends and Challenges in the Clinical Translation of Nanoparticulate Nanomedicines: Pathways for Translational Development and Commercialization.Frontiers in pharmacology · 2018Review
- Editorial: Advances and Challenges in Nanomedicine.Frontiers in pharmacology · 2018Article
- Overcoming multidrug resistance through inhalable siRNA nanoparticles-decorated porous microparticles based on supercritical fluid technology.International journal of nanomedicine · 2018Article
- [Construction and verification of anti-MM scFv-tP fusion protein expression vector].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2017Article
- Review
- Polymers in the Delivery of siRNA for the Treatment of Virus Infections.Topics in current chemistry (Cham) · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The promise of RNA interference (RNAi) technology in cancer therapeutics aims to deliver small interfering RNA (siRNA) for silencing of gene expression in cell type-specific pathway. However, the challenge for the delivery of stable siRNA is hindered by an immune-hostile tumor microenvironment and physiological barriers of the circulatory system. Therefore, the development and validation of safe, stable, and efficient nanoengineered delivery systems are highly essential for effective delivery of siRNA into cancer cells. This review focuses on gene-silencing mechanisms, challenges to siRNA delivery, design and delivery of nanocarrier systems, ongoing clinical trials, and translational prospects for siRNA-mediated cancer therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.